Ireland
--:--IST
Enrolling by invitation Not applicable

Vascular Access and Intraosseus

NCT07471555 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2026-04-02
Last updated
2026-04-29

Condition(s) studied

To Compare the Time Required to Administer 1 mg of Epinephrine, as Well as the Total Procedure

Investigational drug(s) / intervention(s)

Epinephrine Ampoule (Manual Preparation)Epinephrine Prefilled Syringe (Ready-to-use)Intravenous (IV) AccessIntraosseous (IO) Access Device

Epinephrine Ampoule (Manual Preparation): Standard 1 mg/mL glass ampoule requiring manual aspiration with a needle and syringe before administration.

Epinephrine Prefilled Syringe (Ready-to-use): Ready-to-use 1 mg/10 mL prefilled syringe system for immediate administration.

Intravenous (IV) Access: Peripheral venous cannulation procedure.

Intraosseous (IO) Access Device: Manual or powered intraosseous drill/needle for vascular access.

Study summary

Rapid administration of epinephrine is an essential component of advanced life support during cardiac arrest. Peripheral intravenous (IV) access is commonly used for drug delivery, while intraosseous (IO) access is an alternative when IV access is not readily available. In addition, epinephrine may be administered using different drug presentations, such as ampoules or prefilled syringes, which may influence procedural workflow during resuscitation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * 4th year Nursing students Exclusion Criteria: * 1-2-3 th year Nursing students

Primary outcome measure(s)

  • Total Time for Epinephrine Administration. — During the simulation procedure (Day 1)
    The interval of time (in seconds) from the instruction to begin the procedure until the complete administration of 1 mg of epinephrine into the simulation device.

Trial sites (1)

FacilityCityRegionStatus
Faculty of Nursing and Podiatry Valencia Valencia
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07471555 on ClinicalTrials.gov ↗ ← All trials in Spain